4.64
Schlusskurs vom Vortag:
$4.17
Offen:
$4.26
24-Stunden-Volumen:
1.59M
Relative Volume:
2.53
Marktkapitalisierung:
$437.64M
Einnahmen:
$9.01M
Nettoeinkommen (Verlust:
$-99.72M
KGV:
-1.0225
EPS:
-4.5381
Netto-Cashflow:
$-92.85M
1W Leistung:
+16.33%
1M Leistung:
+17.51%
6M Leistung:
+30.06%
1J Leistung:
+217.12%
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Firmenname
X 4 Pharmaceuticals Inc
Sektor
Branche
Telefon
857-529-8300
Adresse
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
XFOR
X 4 Pharmaceuticals Inc
|
4.64 | 371.62M | 9.01M | -99.72M | -92.85M | -4.5381 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.33 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.13 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
864.88 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
205.32 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Eingeleitet | Guggenheim | Buy |
| 2025-12-05 | Fortgesetzt | Stifel | Buy |
| 2023-12-12 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-12-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-12-05 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-07 | Eingeleitet | Stifel | Buy |
| 2019-06-05 | Eingeleitet | Cowen | Outperform |
Alle ansehen
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
Form 4 Olema Pharmaceuticals Inc For: 27 July By Investing.com - Investing.com South Africa
X4 Pharmaceuticals Inc (XFOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
X4 Pharmaceuticals Inc (XFOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
X4 Pharmaceuticals Inc (XFOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
X4 Pharmaceuticals Inc (XFOR) Cash Flow - TradingKey
XFOR|X4 Pharmaceuticals Inc|Price:3.930|Chg%:+0.080 - TradingKey
X4 Pharmaceuticals Inc (XFOR) Balance Sheet - TradingKey
X4 Pharmaceuticals Market Sentiment - Benzinga España
X4 Pharmaceuticals Inc (XFOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
X4 Pharmaceuticals Inc (XFOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
X4 Pharmaceuticals, Inc. Revenue Breakdown – FWB:48Q0 - TradingView
XFOR|X4 Pharmaceuticals Inc|Price:3.850|Chg%:-0.140 - TradingKey
X4 Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:XFOR - TradingView
Form 4 Vertex Pharmaceuticals Inc For: 24 July By Investing.com - Investing.com South Africa
X4 Pharmaceuticals Inc (XFOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
X4 Pharmaceuticals Inc (XFOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com - Investing.com South Africa
Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy - Buffalo News
Frontier tech research, news & data - MLQ.ai
Form 4 Eton Pharmaceuticals Inc For: 17 July By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 17 July By Investing.com - Investing.com Canada
Catalyst Pharma (CPRX) director cashes out stock and options in $31.50 Angelini buyout - Stock Titan
Catalyst Pharmaceuticals (NASDAQ: CPRX) HR chief equity cashed out at $31.50 - Stock Titan
Catalyst Pharmaceuticals (NASDAQ: CPRX) director equity converted to cash at $31.50 - Stock Titan
Catalyst Pharma (NASDAQ: CPRX) CSO’s shares and options canceled in merger - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO equity awards canceled for cash in Angelini merger - Stock Titan
Form 4 Eton Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com Nigeria
Form 4 Adial Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com Canada
Form 4 Phathom Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com Nigeria
Form 4 Shuttle Pharmaceuticals Inc For: 15 July By Investing.com - Investing.com Canada
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now? - TradingView
Form 4 Armata Pharmaceuticals Inc For: 14 July By Investing.com - Investing.com Nigeria
Form 4 Eton Pharmaceuticals Inc For: 14 July By Investing.com - Investing.com Canada
Form 4 Shuttle Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Canada
Form 4 Adial Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Canada
XFOR Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentAdjusted Earnings Analysis - dars.gov.et
X4 Pharmaceuticals (XFOR) Q1 2026 earnings summary - Quartr
X4 Pharmaceuticals (XFOR) Proxy filing Summary - Quartr
X4 Pharmaceuticals (XFOR) Q4 2025 earnings summary - Quartr
X4 Pharmaceuticals (XFOR) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
X4 Pharmaceuticals (XFOR) Corporate presentation Summary - Quartr
X4 Pharmaceuticals (XFOR) Registration filing Summary - Quartr
X4 Pharmaceuticals (XFOR) Rallies 11.36% as Positive Sentiment Drives Price Above Key SupportProfit Surge Picks - Bölüm Sonu Canavarı
Form 4 Rigel Pharmaceuticals Inc For: 10 July By Investing.com - Investing.com Nigeria
Form 4 Sonoma Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Form 4 Shuttle Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
Form 4 Ironwood Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Form 4 Recursion Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals stock focuses on rare disease pipeline after Nasdaq listing - ad-hoc-news.de
Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com Nigeria
Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
X 4 Pharmaceuticals Inc-Aktie (XFOR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KIRSKE DAVID | Chief Financial Officer |
May 12 '26 |
Sale |
4.29 |
16,961 |
72,820 |
176,293 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):